G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference
G1 Therapeutics, a commercial-stage oncology company, announced that CEO Jack Bailey and the executive team will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics, a commercial-stage oncology company, announced that CEO Jack Bailey and the executive team will participate in the H.C. Wainwright 24th Annual Global Investment Conference. The virtual event is scheduled for September 12, 2022, at 7:00 AM ET. A live webcast and replay will be available on the company's Events & Presentations page.
G1 Therapeutics focuses on developing therapies for cancer, notably its first product, COSELA® (trilaciclib), and is advancing a tumor-agnostic development plan targeting various solid tumors.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was +10.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, and other members of the executive team will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference. The fireside chat with G1 will be available at 7:00AM ET on September 12, 2022. The webcast and replay of this event will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
G1 Therapeutics™ and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.
Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.